TG
RPRX icon

TCW Group’s Royalty Pharma RPRX Stock Holding History

TCW Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
+6,193
New +$322K ﹤0.01% 563

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCW Group's RPRX Position: Q2 2026 in Review

TCW Group opened a new position in Royalty Pharma (RPRX) in Q2 2026: 6,193 shares worth $347K. The stake represents ﹤0.01% of the portfolio and ranks #563 among its holdings.

641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • TCW Group held 6,193 shares of Royalty Pharma worth $347K as of Q2 2026.
  • Royalty Pharma was a new TCW Group position in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of TCW Group's portfolio in Q2 2026, its #563 holding.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on TCW Group's 13F filing for Q2 2026, filed 3 Aug 2026.